Thanks for clarifying.

Further to this comment from [0]: "But with Cfp1, the stakes of that specific patent dispute go down. A lab or company could use Cfp1 without infringing on the CRISPR/Cas9 patent. "

[0] http://www.wired.com/2015/09/war-genome-editing-just-got-lot...